David Ricks, chief executive officer of Eli Lilly & Co., at the Semafor World Economy Summit during the International Monetary Fund (IMF) and World Bank Spring meetings in Washington, DC, US, on Friday, April 17, 2026. Aaron Schwartz | Bloomberg | Getty Images Eli Lilly on Thursday reported first-quarter earnings and revenue that blew past estimates and hiked its full-year sales outlook by $2 billion, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro spiked again. The pharmaceutical giant now expects 2026 revenue to come in between $82 billion and $85 billion, up from a previous guidance of $80 billion to $83 billion. Lilly also expects its full-year adjusted profit to be between $35.50 to $37 per share. That compares to a previous outlook of $33.50 to $35 per share.  Resilient demand for Zepbound and Mounjaro has helped fuel several strong quarters for Lilly despite lower prices for the medications in the U.S.…